CP-690550 is a JAK3 inhibitor that is currently in clinical trials for treatment of rheumatoid arthritis, juvenile idiopathic arthritis, ulcerative colitis and other inflammatory conditions. This evidence concerns the gene JAK3 and rheumatoid arthritis.